Gemphire Therapeutics Inc (NASDAQ:GEMP) has earned a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a 12 month consensus price objective of $19.00 for the company and are expecting that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also assigned Gemphire Therapeutics an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of brokerages recently weighed in on GEMP. RBC Capital Markets reissued an “outperform” rating and set a $25.00 price objective on shares of Gemphire Therapeutics in a report on Friday. Royal Bank Of Canada began coverage on Gemphire Therapeutics in a report on Tuesday, August 30th. They set an “outperform” rating and a $25.00 price objective on the stock. Jefferies Group began coverage on Gemphire Therapeutics in a report on Tuesday, August 30th. They set a “buy” rating and a $15.00 price objective on the stock. Laidlaw began coverage on Gemphire Therapeutics in a report on Tuesday, September 6th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Canaccord Genuity assumed coverage on Gemphire Therapeutics in a report on Tuesday, August 30th. They set a “buy” rating and a $17.00 price objective on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/gemphire-therapeutics-inc-nasdaqgemp-given-19-00-consensus-target-price-by-brokerages-2.html

In related news, CEO Mina Sooch purchased 52,500 shares of Gemphire Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $525,000.00. Following the transaction, the chief executive officer now directly owns 693,732 shares in the company, valued at $6,937,320. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Lowenschuss purchased 11,120 shares of Gemphire Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The shares were bought at an average price of $10.00 per share, for a total transaction of $111,200.00. Following the completion of the transaction, the insider now owns 806,247 shares in the company, valued at $8,062,470. The disclosure for this purchase can be found here.

Gemphire Therapeutics (NASDAQ:GEMP) traded up 1.490% during midday trading on Tuesday, reaching $10.149. 4,288 shares of the company traded hands. Gemphire Therapeutics has a 12 month low of $8.80 and a 12 month high of $13.98. The stock’s market capitalization is $94.08 million. The firm has a 50 day moving average of $10.78 and a 200-day moving average of $10.78.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of dyslipidemia. It is developing its product candidate Gemcabene (CI-1027), once-daily, oral therapy, for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

5 Day Chart for NASDAQ:GEMP

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.